AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39206547 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein cluster with caspase-3
Number of subjects: 763
Study 39206547 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein cluster with tumor necrosis factor receptor 1
Number of subjects: 763
Study 39206547 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein cluster with protein C
Number of subjects: 763
Study 39206547 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein clusters at baseline
Number of subjects: 763
Study 39206549 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (threshold, 10 g/dL)
Number of subjects: 3415
Study 39206549 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (threshold, 7-8 g/dL)
Number of subjects: 3415
Study 39206728 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal Hematopoiesis (CH)
Number of subjects: 314
Study 39206728 — intervention group
Group type: COMPARATOR
Intervention: Non-Clonal Hematopoiesis (non-CH)
Number of subjects: 314
Study 39207239 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine delivered via metered-dose inhalation
Number of subjects: 0
Study 39207239 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injection of epinephrine
Number of subjects: 0
Study 39207344 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptans
Number of subjects: 3518
Study 39207344 — intervention group
Group type: COMPARATOR
Intervention: Nontriptan treatments
Number of subjects: 3518
Study 39207396 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine demand
Number of subjects: 0
Study 39207396 — intervention group
Group type: EXPERIMENTAL
Intervention: Anhedonia
Number of subjects: 0
Study 39207422 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle physical activity intervention involving step tracking and psychoeducational materials
Number of subjects: 0
Study 39207422 — intervention group
Group type: COMPARATOR
Intervention: Water tracking (control group)
Number of subjects: 0
Study 39207422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 0
Study 39207423 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE) therapy
Number of subjects: 0
Study 39207423 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39207432 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVED condition (moral elevation intervention)
Number of subjects: 0
Study 39207432 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 39207550 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypropylene onlay mesh
Number of subjects: 116
Study 39207550 — intervention group
Group type: COMPARATOR
Intervention: Control (no polypropylene onlay mesh)
Number of subjects: 116
Study 39207839 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient nipple stimulation therapy via an electric breast pump
Number of subjects: 988
Study 39207839 — intervention group
Group type: COMPARATOR
Intervention: Immediate synthetic oxytocin infusion without nipple stimulation
Number of subjects: 988
Study 39207912 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Care Management With Wearable Devices (mPAP)
Number of subjects: 50
Study 39207912 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 50
Study 39208136 — intervention group
Group type: EXPERIMENTAL
Intervention: Global exercise training
Number of subjects: 70
Study 39208136 — intervention group
Group type: COMPARATOR
Intervention: Handwriting upper limb exercise training
Number of subjects: 70
Study 39208192 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver study visits including the Last Month of Life survey, study-specific questions, and a semi-structured interview.
Number of subjects: 50
Study 39208192 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver experiences during the last month of life.
Number of subjects: 50
Study 39208192 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to information about DLB, support, and hospice care.
Number of subjects: 50
Study 39208192 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospice care utilization.
Number of subjects: 50
Study 39208192 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication, care coordination, quality care, and caregiver education in hospice.
Number of subjects: 50
Study 39208325 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message invitation
Number of subjects: 10844
Study 39208325 — intervention group
Group type: COMPARATOR
Intervention: Letter invitation (control)
Number of subjects: 10844
Study 39208372 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocking of [specific intervention not provided]
Number of subjects: 7
Study 39208374 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted methylation-based MCED test
Number of subjects: 420
Study 39208379 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarlatamab
Number of subjects: 0
Study 39208403 — intervention group
Group type: EXPERIMENTAL
Intervention: NANO-LM consensus scorecard for clinical assessment
Number of subjects: 0
Study 39208412 — intervention group
Group type: EXPERIMENTAL
Intervention: SSMW only
Number of subjects: 456
Study 39208412 — intervention group
Group type: EXPERIMENTAL
Intervention: SSMW+coach
Number of subjects: 456
Study 39208412 — intervention group
Group type: COMPARATOR
Intervention: UWC
Number of subjects: 456
Study 39208425 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-based telehealth intervention including pretest and posttest live AV conferencing sessions, home specimen self-collection for bacterial STI screening.
Number of subjects: 75
Study 39208425 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing-based telehealth intervention.
Number of subjects: 75
Study 39208489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab/nivolumab followed by nivolumab maintenance
Number of subjects: 9
Study 39208489 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinduction with ipilimumab/nivolumab
Number of subjects: 9
Study 39208489 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-free observation period
Number of subjects: 9
Study 39208520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 45
Study 39208776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic optimization according to the study protocol (systolic BP targets: 140-160 mm Hg for mTICI = 2b; 100-140 mm Hg for mTICI = 2c/3) applied within the first 72 hours.
Number of subjects: 0
Study 39208776 — intervention group
Group type: COMPARATOR
Intervention: Current BP management guidelines (≤180/105 mm Hg).
Number of subjects: 0
Study 39208776 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodynamic optimization protocol (systolic BP targets)
Number of subjects: 0
Study 39208825 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab (10 mg/kg per month intravenously or 200 mg per week subcutaneously)
Number of subjects: 3086
Study 39208825 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard therapy
Number of subjects: 3086
Study 39208856 — intervention group
Group type: EXPERIMENTAL
Intervention: pTVG-HP, 100-1500 µg, administered over 12 weeks
Number of subjects: 39
Study 39208856 — intervention group
Group type: EXPERIMENTAL
Intervention: pTVG-HP, 100 µg with different schedules of administration over 1 year
Number of subjects: 39
Study 39208856 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of T-cells specific for the PAP target antigen
Number of subjects: 39
Study 39208947 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA) only
Number of subjects: 107
Study 39209068 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 100/200 mg every 2 weeks
Number of subjects: 347
Study 39209068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 347
Study 39209113 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 100 mg/mL with fixed refill-exchanges every 24 weeks (Q24W)
Number of subjects: 555
Study 39209113 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly intravitreal ranibizumab 0.5-mg injections
Number of subjects: 555
Study 39209113 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 100 mg/mL
Number of subjects: 555
Study 39209113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ladder-to-Portal previous monthly ranibizumab patients
Number of subjects: 555
Study 39209113 — intervention group
Group type: EXPERIMENTAL
Intervention: All-PDS safety population
Number of subjects: 555
Study 39209155 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine intake at 7 different levels over a 3-day period after 2 days of preadaptation to adequate protein intake (1.0 g⋅kg)
Number of subjects: 10
Study 39209155 — intervention group
Group type: EXPERIMENTAL
Intervention: Leucine intake
Number of subjects: 10
Study 39209187 — intervention group
Group type: EXPERIMENTAL
Intervention: Vonoprazan 10 mg once daily
Number of subjects: 208
Study 39209187 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 15 mg once daily
Number of subjects: 208
Study 39209187 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 208
Study 39209203 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g gluten per day
Number of subjects: 13
Study 39209203 — intervention group
Group type: COMPARATOR
Intervention: 3 g gluten per day
Number of subjects: 13
Study 39209203 — intervention group
Group type: EXPERIMENTAL
Intervention: Proteome scores at day 15
Number of subjects: 13
Study 39209369 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) treatment for 12 weeks
Number of subjects: 136
Study 39209438 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve replacement (AVR)
Number of subjects: 52
Study 39209438 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (MT)
Number of subjects: 52
Study 39209452 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoimmunotherapy with camrelizumab, nab-paclitaxel, and carboplatin (Cohort 1, 66 patients)
Number of subjects: 141
Study 39209452 — intervention group
Group type: EXPERIMENTAL
Intervention: Various immune checkpoint inhibitors with (nab-)paclitaxel and platinum-based chemotherapy (Cohort 2, 48 patients)
Number of subjects: 141
Study 39209452 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment of toripalimab with chemotherapy (Cohort 3, 27 patients)
Number of subjects: 141
Study 39209495 — intervention group
Group type: EXPERIMENTAL
Intervention: High-exchange SBUF (H-SBUF) during CPB
Number of subjects: 96
Study 39209495 — intervention group
Group type: COMPARATOR
Intervention: Low-exchange SBUF (L-SBUF) during CPB
Number of subjects: 96
Study 39209498 — intervention group
Group type: EXPERIMENTAL
Intervention: Best Case/Worst Case-ICU intervention
Number of subjects: 0
Study 39209498 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 39209524 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined online and onsite implementation strategy (coach workshop and HSP support)
Number of subjects: 945
Study 39209524 — intervention group
Group type: COMPARATOR
Intervention: Online-only strategy (control group)
Number of subjects: 945
Study 39209730 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine plus dexamethasone 0.1 mg/kg (DEX0.1)
Number of subjects: 90
Study 39209730 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% ropivacaine plus dexamethasone 0.05 mg/kg (DEX0.05)
Number of subjects: 90
Study 39209730 — intervention group
Group type: COMPARATOR
Intervention: 0.5% ropivacaine with saline (control)
Number of subjects: 90
Study 39209770 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care in patients with IBD
Number of subjects: 250
Study 39209770 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver contributions to self-care
Number of subjects: 250
Study 39209778 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive deprescribing
Number of subjects: 0
Study 39209778 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 39209781 — intervention group
Group type: EXPERIMENTAL
Intervention: methylprednisolone (62.5 mg/mL)
Number of subjects: 148
Study 39209781 — intervention group
Group type: COMPARATOR
Intervention: placebo (sodium chloride 0.9%)
Number of subjects: 148
Study 39209782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabatolimab 800 mg every 4 weeks plus spartalizumab 400 mg every 4 weeks until unacceptable toxicity, disease progression and/or treatment discontinuation.
Number of subjects: 33
Study 39209782 — intervention group
Group type: EXPERIMENTAL
Intervention: Sabatolimab plus spartalizumab
Number of subjects: 33
Study 39209823 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (50-µg booster dose)
Number of subjects: 29035
Study 39209823 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (primary vaccination)
Number of subjects: 29035
Study 39209823 — intervention group
Group type: COMPARATOR
Intervention: Placebo-mRNA-1273 (control group)
Number of subjects: 29035
Study 39209823 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNA-1273 (primary vaccination and boosting)
Number of subjects: 29035
Study 39209968 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 0
Study 39209968 — intervention group
Group type: EXPERIMENTAL
Intervention: MoCA
Number of subjects: 0
Study 39210194 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radio-chemotherapy (Group 1, 25 cases)
Number of subjects: 53
Study 39210194 — intervention group
Group type: COMPARATOR
Intervention: No neoadjuvant treatment (Group 2, 28 cases)
Number of subjects: 53
Study 39210194 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant radio-chemotherapy (Group 1)
Number of subjects: 53
Study 39210194 — intervention group
Group type: COMPARATOR
Intervention: No neoadjuvant treatment (Group 2)
Number of subjects: 53
Study 39210299 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipedicle vessel utilization for flap supercharge
Number of subjects: 278
Study 39210299 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior inferior epigastric vein (SIEV) utilization
Number of subjects: 278
Study 39210299 — intervention group
Group type: COMPARATOR
Intervention: SIEV as primary choice for flap supercharge (pre-MIS)
Number of subjects: 278
Study 39210299 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral DIEP pedicle prominence (post-MIS)
Number of subjects: 278
Study 39210299 — intervention group
Group type: EXPERIMENTAL
Intervention: Utilization of thoracodorsal artery and lateral thoracic artery
Number of subjects: 278
Study 39210314 — intervention group
Group type: EXPERIMENTAL
Intervention: START mHealth application
Number of subjects: 250
Study 39210314 — intervention group
Group type: COMPARATOR
Intervention: Website with referrals to HIV care and substance use disorder treatment resources
Number of subjects: 250
Study 39210342 — intervention group
Group type: EXPERIMENTAL
Intervention: Shen Que moxibustion (SQM) + IVF treatment
Number of subjects: 100
Study 39210342 — intervention group
Group type: COMPARATOR
Intervention: IVF treatment alone (Control)
Number of subjects: 100
Study 39210362 — intervention group
Group type: EXPERIMENTAL
Intervention: Rug-weaving plication technique (Group 1)
Number of subjects: 65
Study 39210362 — intervention group
Group type: COMPARATOR
Intervention: Conventional colporrhaphy (Group 2)
Number of subjects: 65
Study 39210388 — intervention group
Group type: EXPERIMENTAL
Intervention: GlobalConsent educational program
Number of subjects: 0
Study 39210388 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-intensity implementation strategies
Number of subjects: 0
Study 39210388 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated surveys with male students
Number of subjects: 0
Study 39210388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost tracking
Number of subjects: 0
Study 39210393 — intervention group
Group type: EXPERIMENTAL
Intervention: Community participatory mapping
Number of subjects: 94
Study 39210431 — intervention group
Group type: EXPERIMENTAL
Intervention: salvage radiotherapy (sRT)
Number of subjects: 101
Study 39210431 — intervention group
Group type: COMPARATOR
Intervention: surveillance-only
Number of subjects: 101
Study 39210431 — intervention group
Group type: EXPERIMENTAL
Intervention: initial ISUP grade 5
Number of subjects: 101
Study 39210472 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg daily for 3 months
Number of subjects: 100
Study 39210472 — intervention group
Group type: COMPARATOR
Intervention: Placebo daily for 3 months
Number of subjects: 100
Study 39210606 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthyretin amyloid cardiomyopathy
Number of subjects: 20
Study 39210725 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 13194
Study 39210725 — intervention group
Group type: COMPARATOR
Intervention: RASi (enalapril or valsartan)
Number of subjects: 13194
Study 39210835 — intervention group
Group type: EXPERIMENTAL
Intervention: Zavegepant 10 mg nasal spray
Number of subjects: 603
Study 39210941 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI diagnosed by stool fecal elastase (FE-1) levels
Number of subjects: 85
Study 39210941 — intervention group
Group type: EXPERIMENTAL
Intervention: Idiopathic AP etiology
Number of subjects: 85
Study 39210941 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately severe or severe AP
Number of subjects: 85
Study 39210941 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline diabetes mellitus
Number of subjects: 85
Study 39210941 — intervention group
Group type: EXPERIMENTAL
Intervention: Index mild attack of AP
Number of subjects: 85
Study 39211037 — intervention group
Group type: EXPERIMENTAL
Intervention: Human umbilical cord-derived mesenchymal stromal cells (UC-MSCs)
Number of subjects: 86
Study 39211540 — intervention group
Group type: EXPERIMENTAL
Intervention: Multichannel tDCS targeting the left DLPFC, 37 sessions of 30 minutes each over 8 weeks (4 weeks daily treatment + 4 weeks taper).
Number of subjects: 35
Study 39211575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Phone Support delivered by phone calls (CPS-C)
Number of subjects: 0
Study 39211575 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell Phone Support delivered by text messages (CPS-T)
Number of subjects: 0
Study 39211575 — intervention group
Group type: COMPARATOR
Intervention: Automated text message reminders (ATR)
Number of subjects: 0
Study 39211745 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored nutritional guidance from a clinical nutritionist and oral health guidance from a dental hygienist
Number of subjects: 220
Study 39211745 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned in the abstract)
Number of subjects: 220
Study 39211748 — intervention group
Group type: EXPERIMENTAL
Intervention: TTViV implantation via femoral vein approach
Number of subjects: 6
Study 39211865 — intervention group
Group type: EXPERIMENTAL
Intervention: Navtemadlin (KRT-232) 120 mg daily
Number of subjects: 21
Study 39211865 — intervention group
Group type: EXPERIMENTAL
Intervention: Navtemadlin (KRT-232) 240 mg daily
Number of subjects: 21
Study 39211865 — intervention group
Group type: EXPERIMENTAL
Intervention: Navtemadlin (KRT-232)
Number of subjects: 21
Study 39211964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucocorticoid (methylprednisolone, 250 mg)
Number of subjects: 530
Study 39211964 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 39212045 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher left ventricular (LV) mass index
Number of subjects: 1097
Study 39212045 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher E/average e' ratio
Number of subjects: 1097
Study 39212045 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher LV mass and volume
Number of subjects: 1097
Study 39212045 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired right ventricular structure and function
Number of subjects: 1097
Study 39212045 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite renal outcome (≥50% decline in estimated glomerular filtration rate, development of end-stage renal disease, or death attributable to renal causes)
Number of subjects: 1097
Study 39212246 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose digoxin
Number of subjects: 1002
Study 39212246 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1002
Study 39212270 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of RASIs until the day of surgery (n=1107)
Number of subjects: 2222
Study 39212270 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of RASIs 48 hours prior to surgery (n=1115)
Number of subjects: 2222
Study 39212524 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging (DWI)
Number of subjects: 17
Study 39212524 — intervention group
Group type: COMPARATOR
Intervention: Thermal dosimetry
Number of subjects: 17
Study 39212948 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 211
Study 39212950 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 0
Study 39212950 — intervention group
Group type: COMPARATOR
Intervention: Active surveillance
Number of subjects: 0
Study 39212990 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment (immediate)
Number of subjects: 997
Study 39212990 — intervention group
Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment (starting on day 8)
Number of subjects: 997
Study 39212990 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment (immediate) in patients with PAD
Number of subjects: 997
Study 39212990 — intervention group
Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment (starting on day 8) in patients with PAD
Number of subjects: 997
Study 39212990 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antihypertensive treatment (immediate) in patients without PAD
Number of subjects: 997
Study 39212990 — intervention group
Group type: COMPARATOR
Intervention: Delayed antihypertensive treatment (starting on day 8) in patients without PAD
Number of subjects: 997
Study 39213024 — intervention group
Group type: EXPERIMENTAL
Intervention: Day program attendees
Number of subjects: 0
Study 39213024 — intervention group
Group type: COMPARATOR
Intervention: Propensity score-matched cohort of older nonattendees
Number of subjects: 0
Study 39213031 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 9672